ST. LOUIS – Head and neck melanoma among pediatric, adolescent and young adult populations in the United States and Canada increased by 51.1% from 1995 to 2014, per research from Saint Louis University.
Archive | Health Professionals
Incidence of pediatric, adolescent and young adult head and neck melanoma is up 51 percent
Posted in Melanoma News, Health Professionals, Of Interest
Promising Data on the Combination of Dabrafenib and Trametinib in BRAF V600-Mutant Melanoma
Ryan Sullivan, MD, associate director, Melanoma Program, Massachusetts General Hospital Cancer Center, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.
Posted in Melanoma News, Health Professionals, Video Reports
TKI Combination vs Monotherapy for Advanced Melanoma and the Risk for CV Adverse Events
Risks of high-grade arterial hypertension and high-grade reduction in left ventricular ejection fraction (LVEF) are increased for patients with advanced melanoma treated with a combination of BRAF and MEK inhibitors compared with those treated with BRAF inhibitor alone, according to study results published in JAMA Open Network.
Posted in Melanoma News, Health Professionals, Of Interest
Head and neck melanoma characteristics
Clinicians should be aware of higher risk cutaneous head and neck melanoma (CHNM) lesions and their potentially worse prognosis when considering appropriate therapies for their patients.
Posted in Melanoma News, Health Professionals, Of Interest
